Clinical Overview
Vilazodone is a novel antidepressant that combines serotonin reuptake inhibition with partial agonism at 5-HT1A receptors, indicated for major depressive disorder. This dual mechanism may provide antidepressant efficacy with reduced sexual side effects and anxiety compared to traditional SSRIs, while potentially offering faster onset of action.
Primary Clinical Applications
Vilazodone is indicated for the treatment of major depressive disorder in adults. It may be particularly suitable for patients who experience sexual side effects with SSRIs or those with comorbid anxiety symptoms. The partial 5-HT1A agonism may provide anxiolytic effects and reduce some SSRI-associated side effects.
Mechanism and Clinical Benefits
Vilazodone inhibits serotonin reuptake while simultaneously acting as a partial agonist at presynaptic 5-HT1A autoreceptors and postsynaptic 5-HT1A receptors. This combination may enhance serotonergic neurotransmission while reducing side effects typically associated with excessive serotonin activity, such as sexual dysfunction and anxiety.
Clinical Considerations
Vilazodone must be taken with food to ensure adequate absorption – bioavailability is significantly reduced when taken on an empty stomach. The medication requires gradual dose titration over the first week to minimize gastrointestinal side effects. It has a relatively favorable side effect profile but commonly causes nausea and diarrhea during initiation.
Prescribing Information
Dosing & Administration
Major Depressive Disorder – Adults:
- Initial: 10 mg once daily with food for 7 days
- Week 2: Increase to 20 mg once daily with food
- Week 3+: Increase to 40 mg once daily with food (target dose)
- Maximum: 40 mg once daily
Dose Adjustments:
- Strong CYP3A4 inhibitors: Maximum 20 mg daily
- CYP2C19 poor metabolizers on CYP3A4 inhibitors: Maximum 20 mg daily
Administration:
- Critical: Take with food to ensure adequate absorption
- Same time each day for consistency
- Swallow tablets whole
Indications
- Treatment of major depressive disorder in adults
Contraindications
- Hypersensitivity to vilazodone
- Use with MAOIs (within 14 days)
- Use with linezolid or IV methylene blue
Warnings & Precautions
- Boxed Warning: Increased risk of suicidal thoughts and behavior in patients under 25 years
- Serotonin syndrome: Risk with concurrent serotonergic drugs
- Activation of mania: Monitor in patients with bipolar disorder
- Discontinuation syndrome: Taper gradually when stopping
- Abnormal bleeding: Increased risk with anticoagulants
- Angle-closure glaucoma: Pupillary dilation may trigger attack
Drug Interactions
- MAOIs: Contraindicated – minimum 14-day washout
- Strong CYP3A4 inhibitors: Reduce vilazodone dose to maximum 20 mg daily
- Strong CYP3A4 inducers: Consider increasing vilazodone dose
- Serotonergic drugs: Increased risk of serotonin syndrome
- NSAIDs, aspirin: Increased bleeding risk
Adverse Reactions
Common (≥5%):
- Diarrhea, nausea, vomiting, insomnia
- Dizziness, dry mouth, abnormal dreams
Advantages:
- Lower rates of sexual dysfunction compared to SSRIs
- Potential anxiolytic effects from 5-HT1A agonism
- May have faster onset than traditional SSRIs
Special Populations
- Hepatic Impairment: No dose adjustment needed for mild-moderate impairment
- Renal Impairment: No dose adjustment needed
- Elderly: No specific dose adjustment required
- Pregnancy: Category C – use only if benefits outweigh risks
- Food requirement: Must take with food for adequate absorption
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
